Second chromosome locus associated with prostate 1 (SChLAP1) (SChLAP1)

Second chromosome locus associated with prostate 1 (SChLAP1) is a long non-coding RNA overexpressed in about 25% of prostate cancers and is highly associated with aggressive disease behavior[1][2][4]. SChLAP1 promotes cancer cell invasion, proliferation, and metastasis both in vitro and in vivo by antagonizing the tumor-suppressive functions of the SWI/SNF chromatin remodeling complex, specifically interfering with genome-wide localization and gene regulatory activity of SWI/SNF components (e.g., SNF5/SMARCB1, BRG1). Mechanistically, SChLAP1 can interact directly with the SWI/SNF complex, disrupt normal chromatin regulation, and further influence gene expression through interactions with other epigenetic regulators such as EZH2, impacting microRNA expression and contributing to cancer progression by repressing tumor-suppressive miRNAs[4][5]. Clinically, SChLAP1 RNA levels serve as an independent biomarker for poor prognosis, higher risk of metastasis, and prostate cancer-specific mortality, being detectable in tissue and urine for non-invasive risk stratification[1][3][4]. Targeting SChLAP1 with antisense oligonucleotides has shown preclinical potential but there are no approved drugs currently.

Other names

PCAT11LINC00913prostate cancer associated transcript 11PCAT114SWI/SNF complex antagonist associated with prostate cancer 1long intergenic non-protein coding RNA 913

Antagonism of the SWI/SNF chromatin remodeling complex[1][2][3][4]; Epigenetic modulation through recruitment of repressive complexes (e.g., EZH2, H3K27me3)[5]